Geripod D Tablet contains a combination of Silodosin 8 mg and Dutasteride 0.5 mg, formulated for the management of benign prostatic hyperplasia (BPH). Silodosin, a selective alpha-1 adrenergic receptor antagonist, facilitates the relaxation of smooth muscle in the bladder neck and prostate, thereby improving urinary flow and reducing symptoms associated with BPH such as urinary frequency, urgency, and nocturia. Dutasteride, a 5-alpha-reductase inhibitor, acts by blocking the conversion of testosterone to dihydrotestosterone (DHT), a hormone responsible for prostate enlargement. This dual mechanism not only provides symptomatic relief but also contributes to a reduction in prostate volume over time, potentially decreasing the risk of acute urinary retention and the need for surgical intervention. Geripod D is indicated for adult male patients diagnosed with moderate to severe BPH, particularly those with an enlarged prostate. The combination therapy should be administered under medical supervision, with consideration given to patient history, including cardiovascular status and liver function. Common adverse effects may include dizziness, retrograde ejaculation, and erectile dysfunction. Regular monitoring is advised to assess therapeutic response and detect any potential side effects. Geripod D Tablet offers an effective pharmacological approach to improving quality of life in patients suffering from BPH.